Treatment with gilteritinib improved survival and increased remission rates, compared with salvage chemotherapy, among patients with relapsed or refractory FLT3-mutated acute myeloid leukemia.
Kristie L. Kahl
Treatment with SY-1425 in combination with azacitidine induced a 62% complete response rate with incomplete blood count recovery rate among unfit patients with RARA-positive AML.
Treatment with umbralisib monotherapy demonstrated improved overall response rates among patients with follicular lymphoma.
A recent Danish study showed pregnancy loss was not associated with later cancer development among women with various cancer types.